25 July 2019 
EMA/CHMP/406684/2019  
Human Medicines Evaluation Division 
Statement indicating compliance with the agreed completed 
paediatric investigation plan  
Medicinal product  
Lucentis/ ranibizumab 
Pharmaceutical form: 
See Annex A of the CHMP Opinion 
Strength: 
Route of administration: 
See Annex A 
See Annex A 
Packaging and package sizes: 
See Annex A 
Numbers in the Community 
See Annex A 
Register of Medicinal Products: 
Marketing Authorisation Holder (MAH): 
Name and address of the MAH:  Novartis Europharm Limited 
Vista Building 
Elm Park, Merrion Road 
Dublin 4 
IRELAND 
Procedure  
Procedure number: 
EMEA/H/C/000715/II/0074/G 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in 
accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
the development of this product has complied with all measures in the agreed paediatric investigation 
plan P/0010/2017. For the purpose of the application of Article 45(3) of Regulation (EC) No 1901/2006, 
significant studies in the agreed paediatric investigation plan P/0010/2017 were completed after the 
entry into force of that Regulation; 
-the Summary of Product Characteristics reflects the results of studies conducted in compliance with this 
agreed paediatric investigation plan. 
In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating compliance 
with the agreed completed paediatric investigation plan P/0010/2017 is included in the technical dossier. 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
 
  
 
 
 
 
 
 
 
  
